Literature DB >> 9789703

Doxorubicin-induced cardiomyopathy treated with carvedilol.

S Fazio1, E A Palmieri, B Ferravante, F Bonè, B Biondi, L Saccà.   

Abstract

Even today, heart failure due to doxorubicin-induced dilated cardiomyopathy seems to have a poor prognosis, as it is often irreversible and relatively unresponsive to standard medical treatment. This paper describes the first case of a patient complaining of severe symptoms of congestive heart failure due to doxorubicin-induced dilated cardiomyopathy unresponsive to standard medical treatment (digoxin, diuretics, and angiotensin-converting enzyme inhibitor), who showed complete clinical recovery and significant improvement of left ventricular dysfunction after carvedilol treatment. It also illustrates the possibility that carvedilol may be a first-choice drug for the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789703      PMCID: PMC6655455          DOI: 10.1002/clc.4960211017

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  9 in total

1.  Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Carlo Maria Cipolla
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-12

Review 2.  Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts.

Authors:  Gina Biasillo; Carlo M Cipolla; Daniela Cardinale
Journal:  Curr Oncol Rep       Date:  2017-08       Impact factor: 5.075

3.  Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.

Authors:  Kisho Ohtani; Takeo Fujino; Tomomi Ide; Kouta Funakoshi; Ichirou Sakamoto; Ken-Ichi Hiasa; Taiki Higo; Kenjiro Kamezaki; Koichi Akashi; Hiroyuki Tsutsui
Journal:  Clin Res Cardiol       Date:  2018-10-26       Impact factor: 5.460

Review 4.  Chemotherapy-induced cardiotoxicity.

Authors:  Amir Y Shaikh; Jeffrey A Shih
Journal:  Curr Heart Fail Rep       Date:  2012-06

Review 5.  Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

Authors:  Danielle Harake; Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Future Cardiol       Date:  2012-07

Review 6.  Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors:  Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal:  Clin Biochem       Date:  2014-11-07       Impact factor: 3.281

7.  Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

Authors:  E Peres; J E Levine; Y A Khaled; R B Ibrahim; T M Braun; O I Krijanovski; S Mineishi; M H Abidi
Journal:  Bone Marrow Transplant       Date:  2009-05-25       Impact factor: 5.483

8.  Cardio-oncology: a new medical issue.

Authors:  D Cardinale; A Colombo; G Lamantia; N Colombo; M Civelli; G De Giacomi; C Pandini; M T Sandri; C M Cipolla
Journal:  Ecancermedicalscience       Date:  2008-12-15

9.  Regulation of Transplanted Cell Homing by FGF1 and PDGFB after Doxorubicin Myocardial Injury.

Authors:  Mark Baguma-Nibasheka; Tiam Feridooni; Feixiong Zhang; Kishore B S Pasumarthi
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.